Carcinoma, Renal Cell: all 1,992 studies
Page 14 of 20. Open to participants first (387), then studies with results posted, then the rest; newest registration first within each.
- Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver TumorsStatus unknownNCT03149523
- Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent NivolumabWithdrawnNCT03149159Phase 2
- Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCCCompletedNCT03136627Phase 1/2
- Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)CompletedNCT03133286
- Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and NivolumabCompletedNCT03126331Phase 2
- Study of the Impact of VEGF Polymorphism on the Development of Renal Carcinoma in Renal Transplant PatientsCompletedNCT03114826
- Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell CancerWithdrawnNCT03111901Phase 1/2
- Assessment of QoL and Outcomes With SBRT for RCCActive, not recruitingNCT03108703Not applicable
- ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to SunitinibCompletedNCT03097601
- CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell CarcinomaStatus unknownNCT03095040Phase 3
- Comparison Between Partial Nephrectomy and Ablation for Renal TumorStatus unknownNCT03094949Not applicable
- Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney CancerActive, not recruitingNCT03092856Phase 2
- Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With PazopanibCompletedNCT03091465
- Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and MelanomaStatus unknownNCT03086174Phase 1
- Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCCCompletedNCT03075423Phase 2
- Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal CancerCompletedNCT03073395Phase 1
- INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological CancersCompletedNCT03071328Early Phase 1
- Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.CompletedNCT03066427Phase 2
- The Assessment of the Feasibility of a Home Based Exercise Programme in the Older Patient Following Major SurgeryCompletedNCT03064308Not applicable
- Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)CompletedNCT03063762Phase 1
- Quality of Life Assessment in Daily Clinical Oncology Practice for Patients With Advanced Renal Cell CarcinomaStatus unknownNCT03062410Not applicable
- Prospective Versus Retrospective Complications in Radical Cystectomy and NephrectomyCompletedNCT03052504
- A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid TumorsStatus unknownNCT03050047Phase 1
- Study of DC-CTL Combined With CIK for Advanced Solid TumorStatus unknownNCT03047525Phase 1/2
- Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell CarcinomaWithdrawnNCT03035630Phase 2
- Everolimus TDM to Predict Long Term ToxicityStatus unknownNCT03033186
- Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line TherapyTerminatedNCT03013946Phase 3
- Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic RegimenCompletedNCT03013335Phase 2
- Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer TypesCompletedNCT03012581Phase 2
- Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic TumoursCompletedNCT02992912Phase 2
- Combining Radiosurgery and Nivolumab in the Treatment of Brain MetastasesCompletedNCT02978404Phase 2
- Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers)Active, not recruitingNCT02978118
- A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)Active, not recruitingNCT02974738Phase 1
- Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)WithdrawnNCT02962804Phase 2
- A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney CancerCompletedNCT02960906Phase 2
- Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease ControlTerminatedNCT02959554Phase 2
- A Safety Study of SGN-2FF for Patients With Advanced Solid TumorsTerminatedNCT02952989Phase 1
- HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell CarcinomaTerminatedNCT02947152Phase 1
- Real-Life Effectiveness and Safety in Participants With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior TherapyCompletedNCT02940639
- Minocycline Attenuate Postoperative Cognitive Dysfunction and DeliriumStatus unknownNCT02928692Phase 3
- Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral AgentsWithdrawnNCT02928263
- Robot-Assisted Laparoscopic Radio Frequency Ablation Assisted Enucleation of Renal Cell Carcinoma With T1a StageStatus unknownNCT02924597Not applicable
- NANOTECH RCC BiomarkersCompletedNCT02923284
- Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)Status unknownNCT02919371Phase 1/2
- Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell CarcinomaCompletedNCT02917772Phase 2
- A Study of PDR001 in Combination With LCL161, Everolimus or PanobinostatCompletedNCT02890069Phase 1
- A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid TumorsStatus unknownNCT02886897Phase 1/2
- Enzalutamide Before Surgery in Treating Patients With Kidney CancerTerminatedNCT02885649Early Phase 1
- Zirconium-89-girentuximab PET/CT Imaging in Renal Cell CarcinomaCompletedNCT02883153Phase 2/3
- Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL)Status unknownNCT02880943Phase 1/2
- PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.WithdrawnNCT02867332Phase 1
- Safety and Preliminary Efficacy of SBRT in Patients With Metastatic RCC Treated With Targeted or IO TherapyCompletedNCT02864615Not applicable
- Ablative tReatment of Inoperable REnal Cell Carcinoma Using STereotactic Body Radiotherapy (ARREST-study)TerminatedNCT02853162Phase 2
- Evaluation of the Efficacy of Radiofrequency in the Treatment of Renal TumorsCompletedNCT02850809
- Impact of the PRISM-care Multidisciplinary Oncology Program on Secured Drug Intake of Patients With Kidney CancerStatus unknownNCT02849535Not applicable
- Transperitoneal vs Retroperitoneal Laparoscopic or Robotic Partial NephrectomyStatus unknownNCT02849119Not applicable
- Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney CancerCompletedNCT02843607Phase 1/2
- A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell CarcinomaTerminatedNCT02837991Phase 1
- Study of Nintedanib Plus Bevacizumab in Advanced Solid TumorsCompletedNCT02835833Phase 1
- MEDI4736 Combinations in Metastatic Renal Cell CarcinomaCompletedNCT02819596Phase 2
- Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study)CompletedNCT02809404
- DC1s-CTL Cellular Therapy for Renal Cell CarcinomaStatus unknownNCT02787915Phase 1/2
- A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients.Status unknownNCT02774200Phase 2
- sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney CancerTerminatedNCT02767921Phase 1
- An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or OpdivoWithdrawnNCT02763761Phase 2
- Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell CarcinomaCompletedNCT02762006Phase 1
- Assessment of Bone Biomarkers for TKI Response in RCC With Bone Metastases, HRQoL and Comparison of Imaging TechniquesTerminatedNCT02747173
- Glycosaminoglycan Scores as Monitoring Biomarkers in Advanced Renal Cell CarcinomaCompletedNCT02732665
- Glycosaminoglycan Scores as Monitoring Biomarkers in Confined Renal Cell CarcinomaCompletedNCT02732652
- Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal CordActive, not recruitingNCT02713269Phase 2
- Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic FactorsCompletedNCT02700568Phase 2
- Study to Assess Various Sunitinib Schedules in Renal Cell CarcinomaStatus unknownNCT02689167Phase 2
- Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN ProjectCompletedNCT02685553Phase 1
- NCCN Renal Cell RegistryCompletedNCT02677337Not applicable
- Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing CryosurgeryWithdrawnNCT02671552Early Phase 1
- Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney CancerActive, not recruitingNCT02664883
- Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced CancersCompletedNCT02655822Phase 1
- TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid TumorsTerminatedNCT02650635Phase 1
- Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid TumorsCompletedNCT02646748Phase 1
- Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR MutationsCompletedNCT02646319Early Phase 1
- Safety Study of MGD009 in B7-H3-expressing TumorsTerminatedNCT02628535Phase 1
- A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian PopulationTerminatedNCT02626754Phase 2
- Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney CancerCompletedNCT02626130Early Phase 1
- Focal Ablative STereotactic Radiosurgery for Cancers of the KidneyCompletedNCT02613819Phase 2
- Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMACompletedNCT02607553Phase 2
- A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC PatientsCompletedNCT02599779Phase 2
- Nivolumab in Treating Patients With High-Risk Kidney Cancer Before SurgeryTerminatedNCT02595918Phase 1
- Whey Protein Supplement in Combination With Physical Exercise and Nutrition ProgramCompletedNCT02585362Not applicable
- Study of the Combination of CM082 With Everolimus in Patients With mRCCStatus unknownNCT02577458Phase 1
- Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell CarcinomaCompletedNCT02575222Phase 1
- Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF TherapyTerminatedNCT02570789Phase 4
- Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)Active, not recruitingNCT02568267Phase 2
- Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell CarcinomaCompletedNCT02555748Phase 4
- A Study of Varlilumab and Atezolizumab in Patients With Advanced CancerTerminatedNCT02543645Phase 1
- Prospective Patient Reported Outcomes (PRO) Registry in Patients With Advanced Renal Cell CarcinomaCompletedNCT02537743
- Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers DiscoveryTerminatedNCT02535351Phase 3
- Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney TumorsCompletedNCT02526511Not applicable
- Prospective Validation of Circulating Tumor Cells & Circulating Endothelial Cells as Biomarkers in Renal CancerCompletedNCT02499458
- Intraoperative Dual-modality Imaging in Renal Cell CarcinomaStatus unknownNCT02497599Phase 1
- Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsActive, not recruitingNCT02496208Phase 1